Fate Therapeutics Inc financial data

Symbol
FATE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
12278 Scripps Summit Drive, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 878 % +46.3%
Return On Equity -44.1 % +0.11%
Return On Assets -32.7 % -3.22%
Operating Margin -1.59K % -682%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 114M shares +15.5%
Common Stock, Shares, Outstanding 114M shares +15.6%
Entity Public Float 462M USD
Common Stock, Value, Issued 114K USD +15.2%
Weighted Average Number of Shares Outstanding, Basic 117M shares +19.4%
Weighted Average Number of Shares Outstanding, Diluted 117M shares +19.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 12.3M USD -89.7%
Research and Development Expense 133M USD -51.4%
General and Administrative Expense 75M USD -14.5%
Operating Income (Loss) -196M USD +19.2%
Net Income (Loss) Attributable to Parent -176M USD +16.9%
Earnings Per Share, Basic -1.71 USD/shares +21.2%
Earnings Per Share, Diluted -1.71 USD/shares +21.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.9M USD -21.1%
Accounts Receivable, after Allowance for Credit Loss, Current 1.05M USD -63%
Assets, Current 319M USD -18.6%
Property, Plant and Equipment, Net 87.5M USD -17.7%
Operating Lease, Right-of-Use Asset 59.5M USD -6.58%
Other Assets, Noncurrent 9K USD -72.7%
Assets 529M USD -9.57%
Accounts Payable, Current 5.5M USD -26.8%
Accrued Liabilities, Current 22.7M USD -23.1%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 34.8M USD -22.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 93.9M USD -6.61%
Accumulated Other Comprehensive Income (Loss), Net of Tax -422K USD +28.1%
Retained Earnings (Accumulated Deficit) -1.3B USD -15.7%
Stockholders' Equity Attributable to Parent 397M USD -9.31%
Liabilities and Equity 529M USD -9.57%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.4M USD -15.6%
Net Cash Provided by (Used in) Financing Activities 95.5M USD +46029%
Net Cash Provided by (Used in) Investing Activities 17.3M USD +85.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 114M shares +15.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 79.5M USD
Deferred Tax Assets, Valuation Allowance 324M USD +9.36%
Deferred Tax Assets, Gross 343M USD +8.11%
Operating Lease, Liability 101M USD -5.44%
Payments to Acquire Property, Plant, and Equipment 86K USD -97.3%
Lessee, Operating Lease, Liability, to be Paid 156M USD -8.53%
Property, Plant and Equipment, Gross 144M USD +2.89%
Operating Lease, Liability, Current 6.64M USD +14.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15.5M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 15.1M USD +2.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 55.1M USD -13.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 113M USD +33.3%
Preferred Stock, Shares Issued 2.76M shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 59.7M USD +13.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15.1M USD -5.93%
Additional Paid in Capital 1.7B USD +8.64%
Preferred Stock, Shares Outstanding 2.76M shares
Depreciation, Depletion and Amortization 4.82M USD +15%
Share-based Payment Arrangement, Expense 40.2M USD -35.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%